%PDF-1.4
%
69 0 obj
<>
endobj
66 0 obj
<>
endobj
135 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-10-07T08:52:46Z
2024-03-28T13:46:29-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T13:46:29-07:00
application/pdf
Heather
2002-1034.nov
uuid:bcea8405-1dd1-11b2-0a00-c808271d5700
uuid:bcea8407-1dd1-11b2-0a00-bf0000000000
endstream
endobj
55 0 obj
<>
endobj
56 0 obj
<>
endobj
70 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 41 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 43 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
26 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
161 0 obj
[166 0 R]
endobj
162 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 420.9531 35.9844 Tm
[(The Journal of Rheumatology 2003; 30:1)74 (1)]TJ
0 Tc 0 Tw -45.8691 -0.0313 Td
(2412)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 10 0 0 10 54 712.495 Tm
(ACKNOWLEDGEMENT)Tj
/T1_2 1 Tf
0.0199 Tc 0.6566 Tw 8 0 0 8 54 702.495 Tm
[(Many thanks to the )55 (Arthritis Foundation of South )55 (Australia)]TJ
-0.00011 Tc 0.12421 Tw 0 -1.25 TD
[(Lupus/Scleroderma/Sj\232gren\325)55 (s Support Group and the many patients with)]TJ
0.0598 Tw T*
[(Sj\232gren\325)55 (s who took part in these studies. )18 (Thanks also to Dr)55 (. Paul Duggin,)]TJ
0.1763 Tw T*
[(Department of Obstetrics and Gynaecology)65 (, University of )55 (Adelaide, for)]TJ
0.02499 Tw T*
(reviewing the manuscript.)Tj
/T1_1 1 Tf
0 Tw 10 0 0 10 54 638.495 Tm
(REFERENCES)Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 61 628.495 Tm
[(1.)-875 (Jonsson R, Haga H, Gordon )18 (TP)111 (. Sj\232gren\325)55 (s syndrome. In: Koopman)]TJ
1.675 -1.25 Td
[(WJ, editor)55 (. )55 (Arthritis and allied conditions. 14th ed. Philadelphia:)]TJ
0.00729 Tw T*
[(Lippincott W)40 (illiams )-18 (& W)40 (ilkins; )-18 (2001:1736-59.)]TJ
0.02499 Tw -1.675 -1.25 Td
[(2.)-875 (W)80 (aterman SA, Gordon )18 (TP)111 (, Rischmueller M. Inhibitory ef)18 (fects of)]TJ
1.675 -1.25 Td
(muscarinic receptor autoantibodies on parasympathetic )Tj
T*
[(neurotransmission in Sjogren\325)55 (s syndrome. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2000;43:1647-54.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875 (Sutclif)18 (fe N, Stoll )18 (T)74 (, Pyke S, Isenber)18 (g DA. Functional disability and)]TJ
1.675 -1.25 Td
[(end or)18 (gan damage in patients with systemic lupus erythematosus)]TJ
T*
[(\(SLE\), SLE and Sjogren\325)55 (s syndrome \(SS\), and primary SS. )]TJ
T*
(J Rheumatol 1998;25:63-8.)Tj
-1.675 -1.25 Td
[(4.)-875 (Barry MJ, Fowler FJ Jr)40 (, O\325Leary MP)111 (, et al. )18 (The )55 (American)]TJ
1.675 -1.25 Td
[(Urological )55 (Association symptom index for benign prostatic )]TJ
T*
[(hyperplasia. )18 (The Measurement Committee of the )55 (American)]TJ
T*
[(Urological )55 (Association. J Urol 1992;148:1549-57; discussion 1564.)]TJ
-1.675 -1.25 Td
[(5.)-875 (Hines JE. Symptom indices in bladder outlet obstruction. Br J Urol)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(1996;77:494-501.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875 (Lepor H, Machi G. Comparison of )55 (AUA)-220 (symptom index in )]TJ
1.675 -1.25 Td
(unselected males and females between fifty-five and seventy-nine)Tj
T*
(years of age. Urology 1993;42:36-40; discussion 40-1.)Tj
-1.675 -1.25 Td
[(7.)-875 (Muscatello DJ, Rissel C, Szonyi G. Urinary symptoms and )]TJ
1.675 -1.25 Td
(incontinence in an urban community: prevalence and associated)Tj
T*
(factors in older men and women. Intern Med J 2001;31:151-60.)Tj
-1.675 -1.25 Td
[(8.)-875 (Pinnock C, Marshall )18 (VR. )18 (T)35 (roublesome lower urinary tract )]TJ
1.675 -1.25 Td
[(symptoms in the community: a prevalence study)65 (. Med J )55 (Aust)]TJ
0 Tc 0 Tw T*
(1997;167:72-5.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875 (Chancellor MB, Rivas DA. )55 (American Urological )55 (Association)]TJ
1.675 -1.25 Td
(symptom index for women with voiding symptoms: lack of index)Tj
T*
(specificity for benign prostate hyperplasia. J Urol 1993;150:1706-8;)Tj
T*
(discussion 1708-9.)Tj
-2.175 -1.25 Td
[(10.)-875 (Cella D. )18 (The Functional )55 (Assessment of Cancer )18 (Therapy-Anemia)]TJ
2.175 -1.25 Td
[(\(F)74 (ACT)92 (-An\) Scale: a new tool for the assessment of outcomes in)]TJ
T*
(cancer anemia and fatigue. Semin Hematol 1997;34:13-9.)Tj
-2.1381 -1.25 Td
[(1)37 (1.)-875 (Y)100 (ellen SB, Cella DF)80 (, )18 (W)80 (ebster K, Blendowski C, Kaplan E.)]TJ
2.1381 -1.25 Td
(Measuring fatigue and other anemia-related symptoms with the)Tj
T*
[(Functional )55 (Assessment of Cancer )18 (Therapy \(F)74 (ACT\) measurement)]TJ
T*
(system. J Pain Symptom Manage 1997;13:63-74.)Tj
-2.175 -1.25 Td
[(12.)-875 (Johns MW)92 (. )55 (A)-220 (new method for measuring daytime sleepiness: the)]TJ
2.175 -1.25 Td
(Epworth Sleepiness Scale. Sleep 1991;14:540-5.)Tj
-2.175 -1.25 Td
[(13.)-875 (Johns MW)92 (. Reliability and factor analysis of the Epworth)]TJ
2.175 -1.25 Td
(Sleepiness Scale. Sleep 1992;15:376-81.)Tj
-2.175 -1.25 Td
[(14.)-875 (V)60 (itali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary)]TJ
2.175 -1.25 Td
[(criteria for the classification of Sjogren\325)55 (s syndrome. Results of a)]TJ
T*
(prospective concerted action supported by the European)Tj
T*
[(Community)65 (. )55 (Arthritis Rheum 1993;36:340-7.)]TJ
-2.175 -1.25 Td
[(15.)-875 (Rischmueller M, Lester S, Chen Z, et al. HLA)-220 (class II phenotype)]TJ
2.175 -1.25 Td
(controls diversification of the autoantibody response in primary)Tj
T*
[(Sjogren\325)55 (s syndrome. Clin Exp Immunol 1998;1)37 (1)37 (1:365-71.)]TJ
-2.175 -1.25 Td
[(16.)-875 (Chai )18 (TC, Belville )18 (WD, McGuire EJ, Nyquist L. Specificity of the)]TJ
2.175 -1.25 Td
[(American Urological )55 (Association voiding symptom index: )]TJ
T*
(comparison of unselected and selected samples of both sexes. )Tj
T*
(J Urol 1993;150:1710-3.)Tj
30.825 74.4209 Td
[(17.)-875 (V)111 (an de Merwe J, Kamerling R, )55 (Arendsen E, Mulder D, Hooijkaas)]TJ
2.175 -1.25 Td
[(H. Sjogren\325)55 (s syndrome in patients with interstitial cystitis. )]TJ
T*
(J Rheumatol 1993;20:962-6.)Tj
-2.175 -1.25 Td
[(18.)-875 (Sacco F)80 (, Rigon G, Sacchini D. )18 (V)111 (escica instabile e morbo di)]TJ
2.175 -1.25 Td
(Sjogren. Caso clinico [Unstable bladder and Sjogren syndrome.)Tj
T*
(Clinical case]. Minerva Med 1996;87:257-9.)Tj
-2.175 -1.25 Td
[(19.)-875 (Haarala M, )55 (Alanen )55 (A, Hietarinta M, Kiiholma P)111 (. Lower urinary)]TJ
2.175 -1.25 Td
[(tract symptoms in patients with Sjogren\325)55 (s syndrome and systemic)]TJ
T*
(lupus erythematosus. Int Urogynecol J Pelvic Floor Dysfunct)Tj
0 Tw T*
[(2000;1)37 (1:84-6.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(20.)-875 (Sankar )18 (V)129 (, Kok M, Leakan RA, Pillemer SR. )18 (The prevalence of)]TJ
2.175 -1.25 Td
[(urinary tract symptoms in patients with Sj\232gren\325)55 (s syndrome)]TJ
T*
[([abstract]. )55 (Arthritis Rheum 2001; Suppl 44:S142.)]TJ
-2.175 -1.25 Td
[(21.)-875 (V)111 (an De Merwe JP)111 (, )55 (Arendsen HJ. Interstitial cystitis: a review of)]TJ
2.175 -1.25 Td
(immunological aspects of the aetiology and pathogenesis, with a)Tj
T*
(hypothesis. BJU Int 2000;85:995-9.)Tj
-2.175 -1.25 Td
[(22.)-875 (Nguyen KH, Brayer J, Cha S, et al. Evidence for antimuscarinic)]TJ
2.175 -1.25 Td
(acetylcholine receptor antibody-mediated secretory dysfunction in)Tj
T*
[(NOD mice. )55 (Arthritis Rheum 2000;43:2297-306.)]TJ
-2.175 -1.25 Td
[(23.)-875 (Newkirk MM. Rheumatoid factors: host resistance or )]TJ
2.175 -1.25 Td
(autoimmunity? Clin Immunol 2002;104:1-13.)Tj
-2.175 -1.25 Td
[(24.)-875 (Emmons RP)111 (, Davis JS, Moretta L. )18 (The ef)18 (fects of IgM rheumatoid)]TJ
2.175 -1.25 Td
(factor on EAM and EAG rosette formation with Fc )Tj
T*
[(receptor)20 (-bearing lymphoid cells. )55 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
(1983;26:1098-103.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(25.)-875 (Godaert GL, Hartkamp )55 (A, Geenen R, et al. Fatigue in daily life in)]TJ
2.175 -1.25 Td
[(patients with primary Sjogren\325)55 (s syndrome and systemic lupus)]TJ
T*
[(erythematosus. )55 (Ann NY)-183 (Acad Sci 2002;966:320-6.)]TJ
-2.175 -1.25 Td
[(26.)-875 (Gudbjornsson B, Broman JE, Hetta J, Hallgren R. Sleep )]TJ
2.175 -1.25 Td
[(disturbances in patients with primary Sjogren\325)55 (s syndrome. Br )]TJ
T*
(J Rheumatol 1993;32:1072-6.)Tj
-2.175 -1.25 Td
[(27.)-875 (Moul DE, Nofzinger EA, Pilkonis P)92 (A, et al. Symptom reports in)]TJ
2.175 -1.25 Td
(severe chronic insomnia. Sleep 2002;25:553-63.)Tj
-2.175 -1.25 Td
[(28.)-875 (Baghdoyan HA, Mallios )18 (VJ, Duckrow RB, Mash DC. Localization)]TJ
2.175 -1.25 Td
(of muscarinic receptor subtypes in brain stem areas regulating)Tj
T*
(sleep. Neuroreport 1994;5:1631-4.)Tj
-2.175 -1.25 Td
[(29.)-875 (Gillette MU, Buchanan GF)80 (, )55 (Artinian L, et al. Role of the M1)]TJ
2.175 -1.25 Td
(receptor in regulating circadian rhythms. Life Sci 2001;68:2467-72.)Tj
-2.175 -1.25 Td
[(30.)-875 (Jokic R, Klimaszewski )55 (A, Mink J, Fitzpatrick MF)80 (. Surface tension)]TJ
2.175 -1.25 Td
(forces in sleep apnea: the role of a soft tissue lubricant: a )Tj
T*
[(randomized double-blind, placebo-controlled trial. )55 (Am J Respir Crit)]TJ
T*
(Care Med 1998;157:1522-5.)Tj
-2.175 -1.25 Td
[(31.)-875 (Research on the menopause in the 1990\325)55 (s. )18 (WHO )18 (T)70 (echnical Report)]TJ
2.175 -1.25 Td
[(Series No. 866. Geneva: )18 (W)80 (orld Health Or)18 (ganisation; 1996.)]TJ
-2.175 -1.25 Td
[(32.)-875 (Brodde OE, Konschak U, Becker K, et al. Cardiac muscarinic)]TJ
2.175 -1.25 Td
(receptors decrease with age. In vitro and in vivo studies. J Clin)Tj
T*
(Invest 1998;101:471-8.)Tj
-2.175 -1.25 Td
[(33.)-875 (Seagrave J, Hildebrand R, Johnson LJ. Muscarinic signalling in)]TJ
2.175 -1.25 Td
[(submandibular salivary acinar cells of ageing rats. )55 (Arch Oral Biol)]TJ
0 Tc 0 Tw T*
(1996;41:425-30.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(34.)-875 (T)70 (ayebati SK, )55 (Amenta F)80 (, El-Assouad D, Zaccheo D. Muscarinic)]TJ
2.175 -1.25 Td
[(choliner)18 (gic receptor subtypes in the hippocampus of aged rats.)]TJ
0 Tc T*
[(Mech )55 (Ageing Dev 2002;123:521-8.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(35.)-875 (Ratz PH, McCammon KA, )55 (Altstatt D, et al. Dif)18 (ferential ef)18 (fects of)]TJ
2.175 -1.25 Td
(sex hormones and phytoestrogens on peak and steady state )Tj
T*
[(contractions in isolated rabbit detrusor)55 (. J Urol 1999;162:1821-8.)]TJ
-2.175 -1.25 Td
[(36.)-875 (Abdalla FM, )55 (Abreu LC, Porto CS. Ef)18 (fect of estrogen on )]TJ
2.175 -1.25 Td
(intracellular signaling pathways linked to activation of M\(2\)- and)Tj
T*
(M\(3\)-muscarinic acetylcholine receptors in the rat myometrium.)Tj
T*
(Mol Cell Endocrinol 2000;160:17-24.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
49 0 obj
<>stream
8;Z\6>B7VH#ikn#j>rjOWs@L:STXeVR4tVh`+onc6o)ON[=;abCj[@TDnQ'uYK,bt
IQmThd@P"VO3bk]H/-H(36%H_c/,A/s/h`TUR
9[hsGQg"jK6f'1tRI9?Cc-r+b%2kG:&cHdCaKu-?BM;Tr:#(j@]l6!Me?8244u.$.
bRV2`S2<[2_s>YAc"SCr=\YFU`2hDkt4H=iWSpRW#iOb>&B0GG=rb&Cp=mb9=c,0&hT'?Lu7G=r\ECO
+W$b<_2C2h1KbHV4n$aBD1ui77kb!$q)oh#D1-e3Ab1l^,XHC]414K!7%BP>'Z\eR
d+d5bO5*3mlEms=DlXW%6`lW4Ef?/jbe#CAPI=jORdh"1!$m6ZKK\R*1GN?3XZ'Zq
9D_#i1f/9koOJZ#S&LJ_j;eKLD`X(q6#QJr,kS+O*'@?88hWZ`75=$CbA$QZ4?Pk]
rR9O32^G]e.r4Sb7]WE?GnHNU[%50&+=taH-sul**K0[Z,>KjRIO_u(:33I'J\SX%
56CljD?SY~>
endstream
endobj
53 0 obj
[/Indexed/DeviceRGB 255 52 0 R]
endobj
52 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
72 0 obj
<>
endobj
29 0 obj
<>
endobj
79 0 obj
<>
endobj
108 0 obj
<>
endobj
140 0 obj
<>
endobj
78 0 obj
<>
endobj
99 0 obj
<>stream
H|SiTY$jJ,*
. ؠmA
AP!@$!J(@e1(j##bkݣrzng&}̯y{}1s3qj/Վ
uXS+8[bƱgcp!,4$BkTR>Xl1߳pomH.*urrDIWnL)u^>֧9/zFIEV\ר 9RgL3V+Wh;LϽJZ\/P㣥mUJ:!Iz.UsR ՅiJyRpS`<cSf"ưDKŰ° vXğٚ]7{G{#Z-ϘL
<{^
?''c\dy7vؖqmW(
/YPZt